Scientific advancements in medicine have led to the development of highly targeted and often high-cost therapies that promise substantial patient benefit but pose significant challenges for payers in terms of value assessment, affordability, and access. McElwee and colleagues (2025) introduce a structured, evidence-based framework to guide payers and manufacturers through the selection and implementation of Alternative Payment Models (APMs) for innovative medicines. They first identify three core contracting challenges—budget impact and uncertainty, value uncertainty, and limitations in the scope of value assessment and negotiation—and then map these to a spectrum of APM solutions such as instalment payments, outcome-based agreements (OBAs), subscription models, and value-based differential pricing (McElwee et al., 2025).
The authors’ first key proposition is that effective APM selection must begin with a clear articulation of the specific problem to be addressed. For example, when a therapy’s short-term budget impact strains annual budgets despite long-term cost-effectiveness, instalment or population-level volume agreements can smooth expenditure over multiple cycles (McElwee et al., 2025). Secondly, they argue that mapping these problems to potential solutions requires a decision guide that captures not only which APMs align with particular challenges but also how multiple models might be combined when more than one problem exists. Their decision guide (Fig. 1 in the original article) serves as a practical tool for stakeholders to navigate choices among APMs based on problem sub-categories such as affordability, uncertainty of effectiveness, and patient heterogeneity (McElwee et al., 2025).
Beyond selecting an appropriate model, the framework emphasizes the necessity of assessing implementation feasibility. Legal, administrative, data-infrastructure, and regulatory barriers can all impede APM execution; the authors present case studies illustrating how pragmatic design choices and collaboration can overcome these obstacles. For example, in a pilot OBA for bevacizumab in non-small cell lung cancer, parties used progression-free survival thresholds and existing electronic health record infrastructures to operationalize rebates without undue administrative burden (McElwee et al., 2025). Similarly, an agreement for gefitinib in Catalonia demonstrated that minimal additional costs and clear stakeholder collaboration can successfully address real-world effectiveness uncertainty (McElwee et al., 2025).
Finally, McElwee et al. (2025) underscore that sustained payer–manufacturer collaboration is essential. Negotiating “win–win” terms requires transparent communication of data requirements, shared assumptions about patient populations, and alignment on outcome metrics. By following their four-step process—articulate the core problem, map to solutions, assess feasibility, and collaborate—stakeholders can more reliably implement APMs that enhance patient access, maintain fiscal sustainability, and continue to incentivize therapeutic innovation.
Reference
McElwee, F., Cole, A., Kaliappan, G., Masters, A., & Steuten, L. (2025). Alternative Payment Models for innovative medicines: A framework for effective implementation. Applied Health Economics and Health Policy, 23(4), 535–549. https://doi.org/10.1007/s40258-025-00960-1
Podcast Link: https://notebooklm.google.com/notebook/d05116cf-78b1-4129-a50e-2f47f0bd61a3/audio